And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far, appears rather modest. We plan to hang with a couple of our short people, catch up on our reading, and take a few naps. These are the lazy, hazy days of summer, after all. And what about you? Will you embark on a summer getaway or firm up plans for one? In any event, this is a lovely time of year to enjoy the great outdoors — beaches, lakes, and mountains are beckoning. You could make time for someone special or, perhaps, plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

The Food and Drug Administration approved or tentatively approved more generic drugs in July than in any other month ever before, Regulatory Focus informs us. Specifically, there were 96 approvals, which followed a steep decline in approvals from earlier in 2018. With the approvals in July also came an annual high in complete response letters that were issued, which amounted to 357, exceeding the previous record of 317 letters issued in October 2017. These letters are sent when the agency declines to approve a drug.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy